At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GLUE Monte Rosa Therapeutics
Market Closed 10-04 16:00:00 EDT
5.09
-0.02
-0.39%
盘后5.09
+0.000.00%
16:01 EDT
High5.31
Low4.97
Vol196.00K
Open5.24
D1 Closing5.11
Amplitude6.66%
Mkt Cap312.36M
Tradable Cap186.28M
Total Shares61.37M
T/O991.17K
T/O Rate0.54%
Tradable Shares36.60M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Monte Rosa Therapeutics Price Target Maintained With a $11.00/Share by Wedbush
Monte Rosa Therapeutics Q2 2024 GAAP EPS $(0.43) Beats $(0.55) Estimate, Sales $4.695M Beat $1.349M Estimate, Cash Position Of $267.1M Is Expected To Fund Operations Into H1 2027
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.